PLRX Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of -31.03%. Pliant Therapeutics, Inc.'s return on equity of -64.22% beat Agenus, Inc.'s return on equity of --.

Pliant Therapeutics, Inc. has a consensus price target of $2.67, signalling upside risk potential of 97.53%. On the other hand Agenus, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 270.37%. Given that Agenus, Inc. has higher upside potential than Pliant Therapeutics, Inc., analysts believe Agenus, Inc. is more attractive than Pliant Therapeutics, Inc..

Pliant Therapeutics, Inc. has a beta of 1.233, which suggesting that the stock is 23.318% more volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. Pliant Therapeutics, Inc.'s net income of -$23.6M is lower than Agenus, Inc.'s net income of -$10.6M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 0.88x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of 16.99%. Pliant Therapeutics, Inc.'s return on equity of -64.22% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

Pliant Therapeutics, Inc. has a consensus price target of $2.67, signalling upside risk potential of 97.53%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that Pliant Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Pliant Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

Pliant Therapeutics, Inc. has a beta of 1.233, which suggesting that the stock is 23.318% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Pliant Therapeutics, Inc.'s net income of -$23.6M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bristol Myers Squibb Co. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of 8.69%. Pliant Therapeutics, Inc.'s return on equity of -64.22% beat Bristol Myers Squibb Co.'s return on equity of 39.9%.

Pliant Therapeutics, Inc. has a consensus price target of $2.67, signalling upside risk potential of 97.53%. On the other hand Bristol Myers Squibb Co. has an analysts' consensus of $62.72 which suggests that it could grow by 5.24%. Given that Pliant Therapeutics, Inc. has higher upside potential than Bristol Myers Squibb Co., analysts believe Pliant Therapeutics, Inc. is more attractive than Bristol Myers Squibb Co..

Pliant Therapeutics, Inc. has a beta of 1.233, which suggesting that the stock is 23.318% more volatile than S&P 500. In comparison Bristol Myers Squibb Co. has a beta of 0.267, suggesting its less volatile than the S&P 500 by 73.293%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol Myers Squibb Co. offers a yield of 4.34% to investors and pays a quarterly dividend of $0.63 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Bristol Myers Squibb Co. pays out 71.98% of its earnings as a dividend. Bristol Myers Squibb Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Bristol Myers Squibb Co. quarterly revenues of $12.5B. Pliant Therapeutics, Inc.'s net income of -$23.6M is lower than Bristol Myers Squibb Co.'s net income of $1.1B. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Bristol Myers Squibb Co.'s PE ratio is 16.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus 2.44x for Bristol Myers Squibb Co.. Usually stocks with elevated PS ratios are considered overvalued.

Savara, Inc. has a net margin of -- compared to Pliant Therapeutics, Inc.'s net margin of --. Pliant Therapeutics, Inc.'s return on equity of -64.22% beat Savara, Inc.'s return on equity of -80.59%.

Pliant Therapeutics, Inc. has a consensus price target of $2.67, signalling upside risk potential of 97.53%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 94.47%. Given that Pliant Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Pliant Therapeutics, Inc. is more attractive than Savara, Inc..

Pliant Therapeutics, Inc. has a beta of 1.233, which suggesting that the stock is 23.318% more volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.316, suggesting its less volatile than the S&P 500 by 68.412%.

Pliant Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Pliant Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.

Pliant Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Pliant Therapeutics, Inc.'s net income of -$23.6M is higher than Savara, Inc.'s net income of -$32.2M. Notably, Pliant Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Pliant Therapeutics, Inc. is 20.40x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.